What is MapLight Therapeutics, Inc. 's change in other assets?

MapLight Therapeutics, Inc. (MPLT) reported change in other assets of -$2.48M in Q1 2026.

What does change in other assets mean?

Change in miscellaneous assets affecting operating cash flow.

MapLight Therapeutics, Inc. MPLT Change in Other Assets

Change in Other Assets at other companies

Acadia PharmaceuticalsACAD

$32K-94.5%

MeiraGTx Holdings plcMGTX

-$1.28M—

Xenon PharmaceuticalsXENE

$1.48M+60.0%

Taysha Gene Therapies, Inc.TSHA

$794K-24.5%

Catalyst PharmaceuticalCPRX

-$2.45M+65.1%

Rapport Therapeutics, Inc.RAPP

-$814K-199%

Other financials

Income statement

See full

Operating income-$64.5M-174%

Net income-$60.7M-172%

EPS (diluted)-$1.34+95.4%

Balance sheet

See full

Cash & equivalents$55.7M—

Total debt$5.6M—

Total equity$399.8M+285%

Total assets$418.8M—

Cash flow

See full

Operating cash flow-$51.2M-100%

CapEx$24.0K—

Free cash flow-$51.2M—

Valuation

See full

Market cap$1.39B—

Enterprise value$1.34B—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity0×—

Current ratio22.9×—

Where this comes from

Reported directly by MapLight Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's change in other assets?: MapLight Therapeutics, Inc. (MPLT) reported change in other assets of -$2.48M in Q1 2026.
What does change in other assets mean?: Change in miscellaneous assets affecting operating cash flow.